Product Description
AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis).
Mechanisms of Action: Angiogenesis Inhibitor,VEGFR Inhibitor
Novel Mechanism: No
Modality: Nondrug
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oragenics
Company Location: TAMPA FL 33634
Company CEO: Kimberly Murphy
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Mucositis|Stomatitis|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Colorectal Cancer
Phase 1: Head and Neck Cancer|Stomatitis|Mucositis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2016-004161-68 | P2 |
Completed |
Head and Neck Cancer|Mucositis |
2020-07-02 |
|
AG013-ODOM-201 | P2 |
Terminated |
Stomatitis|Mucositis |
2020-03-31 |
24% |
SENSOR | P2 |
Completed |
Non-Small-Cell Lung Cancer|Colorectal Cancer |
2019-03-19 |
|
AG013-ODOM-101 | P1 |
Completed |
Mucositis|Stomatitis|Head and Neck Cancer |
2012-09-01 |